UCB struck licensing agreements with Shanghai‑based Antengene to enter the crowded T‑cell engager (TCE) arena, acquiring rights to Antengene’s CD19xCD3 candidate with a mix of upfront payments and potential milestones. The deals give UCB access to Antengene’s AnTenGager platform and position the Belgian immunology heavyweight to compete with large pharmas expanding into bispecifics. Antengene will complete early‑human phase 1 studies before transferring the program; UCB’s deal structure includes near‑term cash to Antengene and up to $1.1 billion in development and commercial milestones in one report, reflecting broad commercial ambitions for bispecifics beyond oncology and into autoimmune indications.